Should Investors Buy Nu Stock After Evaluating Risks?
Nu Holdings ( NYSE: NU ) is a financial services company that operates primarily in Latin America.*Stock prices used were the afternoon prices of May 1, 2025. The video was published on May 3, 2025.Continue reading ...
Worried About Your IRA Savings After Trump's First 100 Days in Office? Read This.
Needless to say, President Donald Trump's first 100 days in office have rattled the stock market. The broader benchmark S&P 500 index fell about 8% during Trump's first 100 days, marking the index's worst performance in this time period since the first 100 days of former President Gerald Ford's ...
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Click Holdings ( NASDAQ:CLIK ) , AGM Gr Hldgs ( NASDAQ:AGMH )
Shares of Faraday Future Intelligent Electric Inc. FFAI rose sharply in pre-market trading. Faraday Future's FX Brand secured second pre-order with 300 FX Super One MPVs from Sky Horse Auto. Faraday Future Intelligent Electric shares jumped 6% to $1.24 in pre-market trading
Aclarion Welcomes Advocate Health as CLARITY Trial Site
• Advocate Health actively participates in research studies and is an innovator in technology, including spine • The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain • Nociscan aims to become the gold standard in identifying ...
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
SALT LAKE CITY, May 05, 2025 ( GLOBE NEWSWIRE ) -- Recursion ( Nasdaq: RXRX ) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its first quarter ended March 31, 2025.
Aclarion Welcomes Advocate Health as CLARITY Trial Site - Aclarion ( NASDAQ:ACONW ) , Aclarion ( NASDAQ:ACON )
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain
